Where Transforming Growth Factor-β (TGF-β) is reported
Also listed as: Fibrotic cytokine; Immunomodulatory cytokine
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| Long COVID | ↑ elevated | healthy controls, recovered individuals without persistent symptoms | Pulmonary symptoms | Lai et al. 2023 |
| ME/CFS | ↑ elevated | healthy controls | Immune regulation, fibrosis signaling | Corbitt et al. 2019 |
Frequently asked questions
In which conditions is Transforming Growth Factor-β (TGF-β) altered?
In the OSMF atlas Transforming Growth Factor-β (TGF-β) is reported in Long COVID, ME/CFS. It is elevated in 2 across 2 entries.
Does Transforming Growth Factor-β (TGF-β) point to one specific diagnosis?
No. Because Transforming Growth Factor-β (TGF-β) changes in several conditions (Long COVID, ME/CFS), an abnormal result cannot identify which condition, if any, is present. It must be interpreted with symptoms, history and other tests.
What is the LOINC code for Transforming Growth Factor-β (TGF-β)?
Entries in this atlas use LOINC 27999-4. LOINC codes identify the laboratory observation so results can be compared across systems.
Is one abnormal Transforming Growth Factor-β (TGF-β) result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.